TIL - NASDAQ
Instil Bio, Inc.
$8.10
-0.84%Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
At a Glance
Live Snapshottil
Research Development Expenses
Last Annual Value
10.00M
3-Year CAGR
-59%
5-Year CAGR
-12%
10-Year CAGR
10%
Instil Bio, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Instil Bio, Inc. NASDAQ:TIL | 10.00M | -36.8% | -37.8% | N/A | |
 Whitehawk Therapeutics Inc NASDAQ:WHWK | 90.96M | 23.0% | 35.8% | N/A | |
 MacroGenics, Inc. NASDAQ:MGNX | 147.17M | -4.0% | -7.3% | 1.9% | |
 Surrozen, Inc. NASDAQ:SRZN | 29.36M | 2.5% | -4.5% | N/A | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 37.19M | -0.0% | 14.9% | N/A | |
 Seer, Inc. NASDAQ:SEER | 43.87M | -2.6% | 8.5% | N/A | |
 Spero Therapeutics, Inc. NASDAQ:SPRO | 38.47M | -9.2% | -9.8% | 3.9% | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 104.89M | 35.3% | 53.5% | N/A | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 114.15M | 9.0% | 20.5% | N/A | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 104.24M | -4.0% | 1.9% | N/A | |
 Inovio Pharmaceuticals, Inc. NASDAQ:INO | 54.21M | -14.5% | -26.3% | -4.8% |
Instil Bio, Inc. Fair Value Envelope
Related Guides
Continue your TIL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.